author-photo

Begoña P. Valderrama

6

Papers

6

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
MP41-12 AVELUMAB FIRST-LINE MAINTENANCE PLUS BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF TIME TO END OF NEXT-LINE THERAPY IN JAVELIN BLADDER 100

2021 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)